Aiming Yu

发表

RNA therapy: Are we using the right molecules?

Mei-Juan Tu, Chao Jian, Ai‐Ming Yu, 2019, Pharmacology & therapeutics.

The Growing Class of Novel RNAi Therapeutics

Gavin M. Traber, Aiming Yu, 2024, Molecular Pharmacology.

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

Mei-Juan Tu, R. D. White, Zhijian Duan, 2017, Oncotarget.

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism

Mei-Juan Tu, Ai-Xi Yu, Zhenzhen Liu, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics

Mei-Juan Tu, Wanrong Yi, Ai-Xi Yu, 2019, Acta pharmaceutica Sinica. B.

Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research

Ai-Ming Yu, Joseph Cronin, Aiming Yu, 2023, Drug Metabolism and Disposition.

Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo

Mei-Juan Tu, Ai-Xi Yu, Aiwen Yu, 2021, Acta Pharmaceutica Sinica. B.

The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

A. Yu, Mei-Juan Tu, Xiang Hu, 2020, Frontiers in Oncology.

Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest

Mei-Juan Tu, Yong Zhao, Ai-Xi Yu, 2016, Scientific Reports.

Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.

Mei-Juan Tu, Yong Zhao, Yifeng Yu, 2015, Biochemical pharmacology.

Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells

A. Yu, Mei-Juan Tu, Zhijian Duan, 2018, Drug Metabolism and Disposition.

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy

Yixian Huang, Haozhe Huang, Zhangyi Luo, 2024, Nature communications.

Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions

A. Yu, Mei-Juan Tu, Wanrong Yi, 2022, Bioengineered.